Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia - Business Wire

Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia  Business Wire

U.S. FDA grants Priority Review for REVLIMID® (lenalidomide) in combination with rituximab (R²) for previously treated follicular and marginal zone lymphoma.



Comments

Post a Comment

Popular posts from this blog

Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC - Cancer Network

Image
In recent years, health care providers have become increasingly concerned around the use of stereotactic radiation for lung cancers that are found near the center of a patient's chest, according to an expert. As a result, Anand Swaminath, MD, and colleagues, wanted not only to assess the efficacy, but also the safety of stereotactic body radiation in a group of patients with inoperable non-small cell lung cancer (NSCLC). Swaminath, an associate professor, clinician scientist, and radiation oncologist at Juravinski Cancer Centre in Ontario, Canada, spoke with CancerNetwork ® during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting and discussed why they compared stereotactic body radiotherapy with a 3-week conventional hypofractionated radiotherapy regimen for patients with stage I medically inoperable NSCLC. Transcript: The standard of care right now for stage I lung cancer is to have surgery. But radiation is a suitable alternative to surgery, and a specifi...
Read more